Growth Metrics

Gyre Therapeutics (GYRE) Operating Leases (2019 - 2025)

Historic Operating Leases for Gyre Therapeutics (GYRE) over the last 7 years, with Q3 2025 value amounting to $539000.0.

  • Gyre Therapeutics' Operating Leases fell 5104.45% to $539000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $539000.0, marking a year-over-year decrease of 5104.45%. This contributed to the annual value of $885000.0 for FY2024, which is 34472.36% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Operating Leases of $539000.0 as of Q3 2025, which was down 5104.45% from $771000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Operating Leases high stood at $1.3 million for Q2 2024, and its period low was $121000.0 during Q4 2022.
  • In the last 5 years, Gyre Therapeutics' Operating Leases had a median value of $771000.0 in 2025 and averaged $668153.8.
  • Per our database at Business Quant, Gyre Therapeutics' Operating Leases plummeted by 7034.31% in 2022 and then surged by 34571.43% in 2025.
  • Gyre Therapeutics' Operating Leases (Quarter) stood at $408000.0 in 2021, then tumbled by 70.34% to $121000.0 in 2022, then skyrocketed by 64.46% to $199000.0 in 2023, then soared by 344.72% to $885000.0 in 2024, then crashed by 39.1% to $539000.0 in 2025.
  • Its Operating Leases was $539000.0 in Q3 2025, compared to $771000.0 in Q2 2025 and $780000.0 in Q1 2025.